Antibodies to oxidised LDL.

Area of Science:

• Immunology
• Cardiovascular Medicine
• Pathology

Background:

• Antibodies to oxidised LDL (low-density lipoprotein) predict myocardial infarction and carotid atherosclerosis progression in prospective studies.
• These antibodies cross-react with antiphospholipid antibodies due to binding oxidised phospholipids.
• Their prevalence and association with arterial thrombosis in SLE and antiphospholipid syndrome suggest a role in accelerated atherosclerosis.

Purpose of the Study:

• To investigate the role of antibodies to oxidised LDL in the development of atherosclerosis.
• To explore the potential atherogenic effects of these antibodies.
• To identify these antibodies as markers for pathogenic determinants of atherosclerosis.

Main Methods:

• Prospective studies analyzing antibody presence and clinical outcomes.
• In vitro studies examining antibody effects on macrophage lipid accumulation.
• Cross-reactivity analysis with antiphospholipid antibodies.

Main Results:

• Antibodies to oxidised LDL are predictive of myocardial infarction and carotid atherosclerosis progression.
• These antibodies exhibit cross-reactivity with antiphospholipid antibodies.
• In vitro data suggest an atherogenic role by enhancing lipid accumulation in macrophages.

Conclusions:

• Antibodies to oxidised LDL are significant predictors of cardiovascular events and atherosclerosis.
• They may contribute to accelerated atherosclerosis in autoimmune conditions like SLE.
• These antibodies serve as markers for key pathogenic factors in atherosclerosis, including lipid oxidation and inflammation.